Key Drivers
- Cash Cushion
- Margin Strength
- Negative FCF
AIAI Summary
Ionis has shifted from a pure pipeline optionality story to an emerging commercial execution story as launches and raised 2026 guidance drive real revenue growth, but the investment still hinges on converting upcoming FDA catalysts into durable free cash flow because losses and cash burn remain too high for the turnaround to be considered self-sustaining.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Margin Strength
- •Negative FCF
IONS has strong liquidity and near-99% gross margins, but persistent operating and free-cash-flow losses, elevated leverage, and a rich sales-based valuation make it a high-risk, funding-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Short-Term Floor
- •Rally Stall
- •Support Risk
Over the last month, IONS has remained range-bound rather than trending, with a rebound from the low-$72s stalling near $77.6-$78.0 and support now centered at $74.0-$74.8.
Sharp rebound from the low-$72s faded quickly after the
Sentiment & News
Key News Insights:
- •Q1 Beat
- •Clinical Progress
- •Ownership Selling
Ionis reported better-than-expected Q1 results and a series of encouraging pipeline and partner milestones, although insider selling and a large stake reduction by Tweedy Browne tempered sentiment.
The update is modestly positive overall, as operational and clinical progress supports the investment case despite lingering ownership and insider-sale overhangs
Similar Companies in Healthcare
Other companies in the same sector with AI ratings